An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

ClinicalTrials.gov ID: NCT01867762

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01867762. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Inhaled JNJ 49095397 (RV568) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the effectiveness and safety of JNJ 49095397 in participants with symptomatic moderate to severe chronic obstructive pulmonary disease (COPD).

Study identification

NCT ID: NCT01867762
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Janssen Research & Development, LLC; Industry
Enrollment: 211 participants

Conditions and interventions

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

JNJ 49095397 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 40 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 9, 2013 (Actual)
Primary completion: Aug 6, 2014 (Actual)
Completion: Sep 1, 2014 (Actual)
Last update posted: Aug 21, 2019

2013 – 2014

United States locations

U.S. sites: 6
U.S. states: 5
U.S. cities: 6

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	—	—
Not listed	St Louis	Missouri	—	—
Not listed	Chapel Hill	North Carolina	—	—
Not listed	Charlotte	North Carolina	—	—
Not listed	Cincinnati	Ohio	—	—
Not listed	Spartanburg	South Carolina	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01867762, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 21, 2019 · Synced Nov 15, 2026